BXCL701

A Phase 1 Study of BXCL701 in Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Myelodysplastic Syndrome With Excess Blasts - 2

What's the purpose of the trial?

The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The names of the study drugs involved in this study are/is: * BXCL701
Trial status

Accepting patients

Phase
Phase 1
Enrollment
24
Last Updated
10 months ago
Am I Eligible

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • BXCL701 is an oral small molecule DPP inhibitor that is being studied for use in several different cancers.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Dose Escalation BXCL701

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.